New treatment for GI and pancreatic NETs The U.S. Food and Drug Administration (FDA) has approved Peptide Receptor Radionuclide Therapy (PRRT) with a new radiopharmaceutical for
Much about a carcinoid cancer cell remains a mystery. For that reason, NETRF funds research to understand how and why a neuroendocrine cancer cell comes
Peptide Receptor Radionuclide Therapy (PRRT) treats neuroendocrine tumors (NETs) by converting a cancer cell’s unique characteristics into a welcome mat for a Trojan Horse packed with cancer-killing radiation.
He is a pioneer whose work has helped extend the horizon of cancer care, creating a new category of individualized immunotherapy. Carl June, MD, has conducted 25 years of scientific research to advance CAR T-cell therapy. And all that knowledge is now helping to tackle NETs.
It is common to feel sad, discouraged, or moody after a cancer diagnosis. You may be facing new limits on what you can do and feel anxious about treatment outcomes and the future. It may be hard to adapt to a new reality and to cope with the changes that come with the diagnosis and the demands of treatment.
This young PNET patient knew something was wrong, but his doctor didn’t believe him. Since this PNET patient was also an oncologist, he asserted the need for further testing to clarify the diagnosis. In a guest blog Mark Lewis, MD, shares insights on listening to your body and getting doctors to listen to you.
Clinical trials are research studies that test how well new drugs, devices, or medical approaches work in people. Through clinical trials, doctors find new ways
The experience of NETs profoundly changes people’s lives. Fatigue, isolation, worry, and bothersome physical side effects can disrupt daily activities. Here are some simple steps to maintain optimal health and balance during and after cancer care.
Study shows rising incidence and prevalence of NETs. Plus people living longer with neuroendocrine cancer. This means more people living with NETs.
